Attn Frederick & Mt. Airy Patients Only: Those offices will be closing at noon on Friday, 6/13.

Trial Protocol ID
USOR 23165_TT420C2308_FIRST-308 *STAR*

A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)

Trial Protocol ID
USOR 23066_TAS-120-205 *STAR*

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements